博瑞医药(688166) - 2025 Q4 - 年度业绩

Financial Performance - In 2025, the company achieved total operating revenue of RMB 122,364.01 million, a decrease of 4.59% year-on-year[7] - The net profit attributable to the parent company was RMB 5,605.64 million, down 70.37% compared to the previous year[7] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 2,401.77 million, a decline of 86.69% year-on-year[7] - Basic earnings per share decreased to RMB 0.13, representing a 71.11% drop from the previous year[4] Assets and Equity - Total assets at the end of 2025 were RMB 579,344.05 million, an increase of 12.43% from the beginning of the year[7] - Equity attributable to the parent company was RMB 248,967.35 million, up 4.46% from the beginning of the year[5] Profit Decline Factors - The significant decline in operating profit and total profit was primarily due to changes in flu trends, competitive landscape, and fluctuations in customer demand[8] - Increased depreciation from completed construction projects and higher R&D expenses contributed to the decline in profits[9] Financial Data Disclaimer - The company emphasizes that the financial data is preliminary and subject to audit, urging investors to be aware of investment risks[10] - The final results will be detailed in the company's 2025 annual report[6]